Takeda Pharmaceutical Co (0RN3) Financial Statements
Takeda Pharmaceutical Co Financial Overview
Takeda Pharmaceutical Co's market cap is currently $60.13B. The company's EPS TTM is $244.85; its P/E ratio is 27.16; and it has a dividend yield of 3.45%. Takeda Pharmaceutical Co is scheduled to report earnings on January 28, 2027, and the estimated EPS forecast is $0.50. See an overview of income statement, balance sheet, and cash flow financials.
| Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 4.51T | $ 4.58T | $ 4.26T | $ 4.03T | $ 3.57T |
| Gross Profit | $ 2.30T | $ 2.46T | $ 2.32T | $ 2.30T | $ 2.04T |
| Operating Income | $ 540.45B | $ 627.54B | $ 531.42B | $ 658.29B | $ 610.50B |
| EBITDA | $ 1.34T | $ 1.13T | $ 927.95B | $ 1.18T | $ 1.04T |
| Net Income | $ 191.76B | $ 107.93B | $ 144.07B | $ 317.02B | $ 230.06B |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 595.05B | $ 385.11B | $ 457.80B | $ 533.53B | $ 849.70B |
| Total Assets | $ 15.45T | $ 14.25T | $ 15.11T | $ 13.96T | $ 13.18T |
| Total Debt | $ 4.88T | $ 5.09T | $ 5.46T | $ 4.86T | $ 4.81T |
| Net Debt | $ 4.29T | $ 4.85T | $ 5.26T | $ 4.63T | $ 3.96T |
| Total Liabilities | $ 7.68T | $ 7.31T | $ 7.83T | $ 7.60T | $ 7.49T |
| Stockholders' Equity | $ 7.77T | $ 6.94T | $ 7.27T | $ 6.35T | $ 5.68T |
| Cash Flow | |||||
| Free Cash Flow | $ 762.71B | $ 761.70B | $ 464.90B | $ 736.56B | $ 897.97B |
| Operating Cash Flow | $ 938.71B | $ 962.49B | $ 640.32B | $ 877.22B | $ 1.02T |
| Investing Cash Flow | $ -387.80B | $ -385.36B | $ -488.21B | $ -615.72B | $ -204.44B |
| Financing Cash Flow | $ -375.44B | $ -638.44B | $ -254.04B | $ -600.59B | $ -962.06B |
Currency in JPY